Abstract
B lymphocyte stimulator (BLyS) is a vital B cell survival factor. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren s syndrome (SS). Treatment with BLyS antagonists of mice with established SLE ameliorates disease progression and enhances survival. Moreover, similar treatment of mice with inflammatory arthritis ameliorates the ongoing inflammation and subsequent joint destruction. In humans, BLyS overexpression is common in patients with several rheumatic diseases, including SLE, rheumatoid arthritis (RA), Sjogren s syndrome, scleroderma, Wegener s granulomatosis, and ANCA-associated vasculitis. Results from phase-II clinical trials with a BLyS antagonist in human SLE and RA have shown the antagonist to have biological and clinical activity along with a favorable safety profile. These features collectively point to BLyS as an attractive therapeutic target in human rheumatic diseases.
Keywords: APRIL, B cells, B lymphocyte stimulator (BLyS), rheumatoid arthritis, Sjogren' s syndrome, systemic lupus erythematosus
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Therapeutic Targeting of B Lymphocyte Stimulator (BLyS) in the Rheumatic Diseases
Volume: 6 Issue: 4
Author(s): William Stohl
Affiliation:
Keywords: APRIL, B cells, B lymphocyte stimulator (BLyS), rheumatoid arthritis, Sjogren' s syndrome, systemic lupus erythematosus
Abstract: B lymphocyte stimulator (BLyS) is a vital B cell survival factor. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren s syndrome (SS). Treatment with BLyS antagonists of mice with established SLE ameliorates disease progression and enhances survival. Moreover, similar treatment of mice with inflammatory arthritis ameliorates the ongoing inflammation and subsequent joint destruction. In humans, BLyS overexpression is common in patients with several rheumatic diseases, including SLE, rheumatoid arthritis (RA), Sjogren s syndrome, scleroderma, Wegener s granulomatosis, and ANCA-associated vasculitis. Results from phase-II clinical trials with a BLyS antagonist in human SLE and RA have shown the antagonist to have biological and clinical activity along with a favorable safety profile. These features collectively point to BLyS as an attractive therapeutic target in human rheumatic diseases.
Export Options
About this article
Cite this article as:
Stohl William, Therapeutic Targeting of B Lymphocyte Stimulator (BLyS) in the Rheumatic Diseases, Endocrine, Metabolic & Immune Disorders - Drug Targets 2006; 6 (4) . https://dx.doi.org/10.2174/187153006779025801
DOI https://dx.doi.org/10.2174/187153006779025801 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Hypertension and Diabetes: Emphasis on the Renin-Angiotensin System in Atherosclerosis
Current Hypertension Reviews Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued) Characterization of the Clinical and Laboratory Features of Primary and Secondary Antiphospholipid Syndrome in a Cohort of Egyptian Patients
Current Rheumatology Reviews Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer
Current Vascular Pharmacology Heat Shock Proteins - Two Sides of a Coin
Current Cardiology Reviews Hematologic Abnormalities in the Antiphospholipid Syndrome
Current Rheumatology Reviews New Antiviral Nucleoside Prodrugs Await Application
Current Medicinal Chemistry Management of Connective Tissue Interstitial Lung Disease
Current Respiratory Medicine Reviews Diffuse Alveolar Hemorrhage, A Potentially Life-Threatening Manifestation in Systemic Lupus Erythematosus and the Antiphospholipid Syndrome
Current Respiratory Medicine Reviews Oxidative Stress in Tumor Angiogenesis - Therapeutic Targets
Current Pharmaceutical Design Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy
Current Pharmaceutical Design Capsule Endoscopy in Crohn’s Disease
Current Drug Targets Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets The Lung Disease of Rheumatoid Arthritis
Current Respiratory Medicine Reviews Severe Influenza: Clinical Features and Treatment Options
Current Respiratory Medicine Reviews Phosphodiesterase Inhibitors as Potential Cognition Enhancing Agents
Current Topics in Medicinal Chemistry Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology Targeting Microenvironment of Melanoma and Head and Neck Cancers in Photodynamic Therapy
Current Medicinal Chemistry High Sensitivity Troponin in Cardiovascular Disease. Is There More Than a Marker of Myocardial Death?
Current Topics in Medicinal Chemistry